Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose patients after a single administration, arrive as analysts publish price targets ranging from $11 to $25 and investors focus on a pivotal near-term event: interim data from the randomized, placebo-controlled RESOLVE Phase 2b study expected in December 2026.

One-Year Data Give the Thesis More Staying Power

Eupraxia’s September 30 clinical update from the ongoing Phase 1b/2a RESOLVE study centered on EP-104GI, its investigational locally delivered, extended-release therapy for eosinophilic esophagitis, or EoE. The headline is not simply that patients responded. It is that a portion of them appeared to remain in remission for a full year following a single treatment. Among patients in Cohorts 5 through 9 who were followed for 52 weeks, 9 of 14 patients, or 64%, remained in clinical remission. In the highest-dose Cohort 9, consisting of patients receiving 20 injections of 8 mg each for a 160 mg total dose, two of three patients, or 66%, maintained clinical remission at Week 52. Clinical remission was defined as at least a three-point improvement from baseline on the Straumann Dysphagia Index, or SDI, which measures the frequency and severity of swallowing difficulty. The company reported a mean SDI reduction of 3.3 points at Week 36 in Cohort 8b, which received the 120 mg regimen through 20 injections of 6 mg. In Cohort 9, the mean SDI reduction was 3.0 points at both Week 36 and Week 52. The data are from a small, open-label dose-escalation study, so they need to be interpreted appropriately. But in EoE, durability is more than a nice clinical adjective—it may be the whole commercial conversation.

“If achieved, an annual dosing regimen could align well with ACG Guidelines supporting routine endoscopic monitoring of EoE patients,” said Dr. James Helliwell, Eupraxia’s Chief Executive Officer, in the company’s announcement.

Tissue Data and Safety Add Support

The update also provided fresh tissue-health data from Cohort 8b. At Week 36, the company reported mean improvements from baseline of 0.26 points in EoEHSS Stage and 0.27 points in EoEHSS Grade. The Eosinophilic Esophagitis Histology Scoring System assesses the extent and severity of inflammatory and fibrotic features observed in esophageal biopsies. This matters because an EoE therapy must ultimately be judged on more than whether swallowing feels easier. A treatment that demonstrates both symptom improvement and signs of reduced tissue inflammation or fibrosis could create a more complete therapeutic argument. Eupraxia also reported no treatment-emergent or procedure-related serious adverse events in the Phase 1b/2a portion of RESOLVE to date. According to the company, no cases of oropharyngeal candidiasis, adrenal insufficiency, or glucose derangement have been reported across the 10 cohorts evaluated so far. Dr. Jeymi Tambiah, Eupraxia’s Chief Medical Officer, said the company has not observed adverse events related to corticosteroid exposure, including abnormal glucose changes. The safety results remain early and will require confirmation in the larger placebo-controlled study. Still, the absence of these events so far supports the company’s case for its Diffusphere platform, which is designed to deliver therapy locally and in a controlled, extended-release fashion. A drug-delivery system that can potentially reduce systemic exposure while preserving efficacy is the kind of proposition that keeps both clinicians and investors from changing the channel.

Analysts Expand the Spotlight

The positive clinical update has coincided with a widening, predominantly constructive Wall Street view of Eupraxia Pharmaceuticals (EPRX). Published analyst price targets currently range from $11 to $25 per share, while aggregated market data place the reported consensus target near $17.80 and describe the broader rating as Moderate Buy.

Martin Auster, M.D., of Raymond James reiterated a Strong Buy rating and an $18 price target after reviewing the new data. Auster’s team said the flow of results continues to reinforce confidence in the potentially differentiated efficacy-and-safety profile of EP-104GI ahead of RESOLVE Part B. The analyst note specifically emphasized the higher-dose cohorts, 120 mg and 160 mg, because those are the exact dose regimens being evaluated in the ongoing randomized Phase 2b study. At the high end of the price-target spectrum, Annabel Samimy of Stifel reiterated a Buy rating and set a $25 target. Meanwhile, Cantor Fitzgerald has maintained an Overweight/$19 stance; Wedbush initiated with an Outperform/$17 assessment; and Oppenheimer initiated with an Outperform/$17 view. Brandon Folkes of H.C. Wainwright maintained a Buy rating and an $11 target. The dispersion between $11 and $25 is not a contradiction so much as a reminder that EPRX is a clinical-stage biotech. Analysts can agree on the potential while disagreeing, quite rationally, on probability of success, timing, commercial adoption, financing needs, and the value assigned to the platform beyond EoE.

December 2026 Is the Event That Counts

The next major milestone is not hidden in the footnotes. Eupraxia expects interim data in December 2026 from the ongoing Phase 2b portion of RESOLVE, a randomized, placebo-controlled study evaluating EP-104GI at the 120 mgand 160 mg dose regimens. The study is currently recruiting. That trial is important because it is designed to test whether EP-104GI’s early signals can withstand the discipline of a controlled comparison. Specifically, investors will be watching for:

• Symptom improvement versus placebo, including changes in dysphagia as measured by SDI.
• The proportion of patients achieving clinical remission.
• Evidence that tissue-health improvements accompany patient-reported symptom improvement.
• Continued tolerability as the program advances into a broader data set.
• Confirmation that the 120 mg and 160 mg dose regimens can support a durable therapeutic effect.

The company expects to disclose additional data from the open-label Phase 1b/2a portion of RESOLVE in the coming months as well. Yet the December interim analysis is the event most likely to influence how investors frame EPRX’s valuation heading into 2027.

The Case: Durability Meets a Defined Catalyst

Eupraxia is developing EP-104GI as a locally administered treatment injected into the esophageal wall. The company believes its Diffusphere technology may provide a stable, prolonged release of active therapy at the targeted tissue site, potentially avoiding the drug-concentration peaks and troughs associated with more conventional delivery methods. EoE itself is a clinically meaningful market opportunity. Eupraxia cites Clearview Healthcare Partners research estimating that more than 450,000 people in the United States are affected by the disease, which involves inflammatory cells accumulating in the esophagus and can cause pain, swallowing difficulty, and substantial day-to-day burden.

The bullish thesis therefore has three moving pieces:

• Durability: 64% of evaluable higher-dose patients remained in clinical remission at 52 weeks after a single treatment in the open-label study.
• Differentiation: Local, extended-release delivery could support an attractive efficacy, tolerability, and dosing proposition if validated in controlled testing.
• Catalyst: December 2026 interim results from the randomized Phase 2b RESOLVE study could materially change the program’s risk-adjusted value.

That is seemingly why the stock has attracted a range of positive recommendations even before the controlled-data readout. Wall Street seems not to be not merely underwriting a single data point; it is assessing whether Eupraxia can turn encouraging one-year observations into a repeatable product profile for a chronic disease.

Bottom Line

Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is entering a more consequential stretch of its clinical and market narrative. Its latest 52-week RESOLVE data showed that 64% of evaluable patients in higher-dose cohorts remained in clinical remission after one EP-104GI administration, while the highest-dose cohort reported a 66% remission rate at one year. The company also reported symptom, tissue-health, and preliminary safety results that support its differentiated local-delivery thesis. Wall Street coverage reflects that potential, with Raymond James’ Martin Auster, M.D., at Strong Buy/$18; Stifel’s Annabel Samimy at Buy/$25; Cantor Fitzgerald at Overweight/$19; Wedbush and Oppenheimer at Outperform/$17; and H.C. Wainwright’s Brandon Folkes at Buy/$11. The next decisive test arrives in December 2026, when Eupraxia expects interim data from its randomized, placebo-controlled Phase 2b RESOLVE study.

Join The Tribe in Nashville To Learn More

If you have not attended one of Tribe Public’s dinners or luncheon events across its 41 U.S. event venues, the format is designed to offer RSVP-only, corporate-sponsored access to management teams and industry experts across a broad range of sectors and investment interests. The gatherings bring together family offices, portfolio managers, accredited investors, business owners, media professionals, and community members interested in hearing directly from corporate leaders while sharing a complimentary, time-efficient private meal. More information is available at Tribe Public. Tribe Public’s next Nashville corporate-sponsored CEO presentation and Q&A dinner, “Precision Matters: Discover How The Future Of Drug Delivery Is Local,” is scheduled for Tuesday, October 13, from 6:00–8:00 PM at the private room at Ruth’s Chris Steak House, 2100 West End Avenue, Nashville, Tennessee 37203.

The evening will feature James A. Helliwell, M.D., Co-Founder, Chief Executive Officer, and Director of Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX). Attendees will have an opportunity to hear directly from Dr. Helliwell about Eupraxia’s precision drug-delivery strategy, its inflammatory-disease clinical focus, and the company’s approach to pursuing localized, extended-release therapies.

About The Speaker. Dr. Helliwell is a board-certified cardiac anesthesiologist and former Assistant Clinical Professor at the University of British Columbia. He founded Eupraxia based on the view that the right medicine, delivered to the right place at the right dose and for the right duration, can improve patient outcomes. His work has appeared in journals including The Lancet Rheumatology, Gastroenterology, and Osteoarthritis & Cartilage. He also founded Accuro Technology, developer of the FDA-approved Arthrotap device, later acquired by Elcam Medical; co-founded Thrive Health; and holds eight granted patents and 35 pending patents related to drug and device delivery.

About The Company. Eupraxia is a clinical-stage biotechnology company advancing localized, extended-release therapies through its proprietary Diffusphere platform. Its lead program, EP-104GI, is in Phase 1b/2 development for EoE, a chronic inflammatory disease in which eosinophils infiltrate the esophagus and can contribute to difficulty or pain with swallowing, food impactions, anxiety, depression, and longer-term esophageal remodeling or strictures.

Space is limited. To reserve a seat, or request seating for friends, family members, or colleagues, email Events@TribePublic.com.

The Sources

1. Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in Its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis Yahoo Finance
2. Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI GlobeNewswire
3. Raymond James Research: “Steady Flow of Data Continues to Support EP-104GI Ahead of RESOLVE Part B” September 30, 2026
4. Stifel Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX), Sets $25 Price Target Markets Insider
5. Wedbush Initiates Eupraxia Pharmaceuticals (EPRX) at Outperform With $17 Price Target Investing.com
6. Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target Yahoo Finance
7. Eupraxia Pharmaceuticals (EPRX) Analyst Coverage Initiated at Wedbush MarketBeat
8. Eupraxia Pharmaceuticals (EPRX) Analyst Forecast and Price Target MarketBeat
9. Eupraxia Pharmaceuticals (EPRX) Consensus Rating and Analyst Coverage MarketBeat
10. Eupraxia Pharmaceuticals (EPRX) Shares Climb as Analyst Coverage and Clinical Catalysts Gain Attention MarketBeat
11. H.C. Wainwright Reissues Buy Rating and $11 Price Target on Eupraxia Pharmaceuticals MarketBeat
12. Eupraxia Announces Updated Data From the Phase 1b/2a RESOLVE Study of EP-104GI Business Insider
13. Eupraxia Pharmaceuticals Reports 52-Week EoE Data for EP-104GI The Globe and Mail / TipRanks
14. Eupraxia Reports 52-Week Data From EoE Treatment Trial Investing.com
15. Eosinophilic Esophagitis: Developing Drugs for Treatment U.S. Food and Drug Administration